Volunteer New York! has announced that seven local volunteers will be honored during its 45th annual Volunteer Spirit Awards ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

President Trump on Tuesday said workers who do not respond to an email from the Office of Personnel Management prompted by ...

Monday was another volatile session for US stock markets, with equities finishing mostly lower after a late-afternoon ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

S&P 500 dips 0.26% as tech stocks weigh on US indices. Traders eye Nvidia earnings and PCE data for market direction. Read ...

Nixon High’s Austlynn Quiroz won the Laredo ISD Science Fair and will compete internationally with her bioplastic project.

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...